{"id":"37ccdd57-dce8-5154-8b10-eb993a3c110e","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-hps-events","predicate":"combination_does_not_reduce","statement":"Niacin–laropiprant produced major vascular-event rates of 13.2% versus 13.7% with placebo: rate ratio 0.96, 95% CI 0.90–1.03, without a significant benefit.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"25ce24fe-8c81-58da-823a-1c3aa4faf5e5","mechanism_event_label":"This large trial also found no clear event benefit when the combination was added to statin treatment.","subject":{"id":"9751fdb6-9b30-586f-b07a-79b8e2cd62dd","slug":"nicotinic-acid","display_name":"Nicotinic acid","entity_type_key":"small_molecule"},"object":{"id":"8f08bd23-f5e8-5787-b7b5-d6e1e26ed99c","slug":"major-cardiovascular-event-incidence","display_name":"Major cardiovascular event incidence","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"25ce24fe-8c81-58da-823a-1c3aa4faf5e5","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-hps-events-event","event_type":"observed_intervention","label":"This large trial also found no clear event benefit when the combination was added to statin treatment.","description":"Niacin–laropiprant produced major vascular-event rates of 13.2% versus 13.7% with placebo: rate ratio 0.96, 95% CI 0.90–1.03, without a significant benefit.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"9ebcef37-189c-5599-b463-108eff6c929a","slug":"laropiprant","display_name":"Laropiprant / MK-0524","entity_type_key":"small_molecule"},"role":"coadministered_drug","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"9751fdb6-9b30-586f-b07a-79b8e2cd62dd","slug":"nicotinic-acid","display_name":"Nicotinic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"8f08bd23-f5e8-5787-b7b5-d6e1e26ed99c","slug":"major-cardiovascular-event-incidence","display_name":"Major cardiovascular event incidence","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"Laropiprant / MK-0524 (coadministered_drug)","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-clinical-sources/hps2014.abstract.txt\", \"locator\": \"Indexed primary abstract\", \"file_sha256\": \"9f12db5e258418187e65c3b921cffd01bf3cc0f400d3caa19cb4005c5e6f4f05\", \"start_char\": 0, \"end_char\": 2717, \"text_sha256\": \"9f12db5e258418187e65c3b921cffd01bf3cc0f400d3caa19cb4005c5e6f4f05\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"HPS2-THRIVE randomized trial; 25,673 adults with vascular disease on statin-based therapy","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Extended-release nicotinic acid 2 g plus laropiprant 40 mg daily; median 3.9 years","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Combination regimen; observed harm cannot all be assigned to nicotinic acid alone. Run-in selected participants able to tolerate initial therapy. Outcomes do not address deficiency replacement.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"This large trial also found no clear event benefit when the combination was added to statin treatment.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[nia-clin-hps2014] Effects of extended-release niacin with laropiprant in high-risk patients. (2014). https://pubmed.ncbi.nlm.nih.gov/25014686/ DOI: 10.1056/nejmoa1300955","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Major vascular events and adverse events","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"129a164c-bfbd-57c2-9af4-4cf69497f82e","evidence_kind":"source_excerpt","locator":"Lines 1403-1415","start_line":1403,"end_line":1415,"excerpt":"### nia-clin-hps-events\nNiacin–laropiprant produced major vascular-event rates of 13.2% versus 13.7% with placebo: rate ratio 0.96, 95% CI 0.90–1.03, without a significant benefit.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: This large trial also found no clear event benefit when the combination was added to statin treatment.\norganism: Homo sapiens\ntissue_or_cell_type: Major vascular events and adverse events\nexperimental_model: HPS2-THRIVE randomized trial; 25,673 adults with vascular disease on statin-based therapy\nlimitations: Combination regimen; observed harm cannot all be assigned to nicotinic acid alone. Run-in selected participants able to tolerate initial therapy. Outcomes do not address deficiency replacement.\nexposure: Extended-release nicotinic acid 2 g plus laropiprant 40 mg daily; median 3.9 years\ncross_nutrient: Laropiprant / MK-0524 (coadministered_drug)\nevidence_span: {\"source_cache\": \"artifacts/niacin-clinical-sources/hps2014.abstract.txt\", \"locator\": \"Indexed primary abstract\", \"file_sha256\": \"9f12db5e258418187e65c3b921cffd01bf3cc0f400d3caa19cb4005c5e6f4f05\", \"start_char\": 0, \"end_char\": 2717, \"text_sha256\": \"9f12db5e258418187e65c3b921cffd01bf3cc0f400d3caa19cb4005c5e6f4f05\"}\n[nia-clin-hps2014] Effects of extended-release niacin with laropiprant in high-risk patients. (2014). https://pubmed.ncbi.nlm.nih.gov/25014686/ DOI: 10.1056/nejmoa1300955","model_system":"HPS2-THRIVE randomized trial; 25,673 adults with vascular disease on statin-based therapy","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [nia-clin-hps2014] Effects of extended-release niacin with laropiprant in high-risk patients. (2014). https://pubmed.ncbi.nlm.nih.gov/25014686/ DOI: 10.1056/nejmoa1300955","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}